ArticleMolecular medicine reports2015
Luteolin exerts an anticancer effect on NCI-H460 human non-small cell lung cancer cells through the induction of Sirt1-mediated apoptosis.
Article in Molecular medicine reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 53 citations in OpenAlex.
- Luteolin protects against cholestasis by suppressing hepatocyte apoptosis through direct PI3K binding and AKT activation.Frontiers in pharmacology · 2026Article
- Mechanism of Brucea javanica against multiple myeloma via TNF-NF-κB signaling.Scientific reports · 2025Article
- Updated Review on Natural Polyphenols: Molecular Mechanisms, Biological Effects, and Clinical Applications for Cancer Management.Biomolecules · 2025Review
- Review
- Radix Codonopsis: a review of anticancer pharmacological activities.Frontiers in pharmacology · 2024Review
- Review
- Application of Polyphenols and Flavonoids in Oncological Therapy.Molecules (Basel, Switzerland) · 2023Review
- α-Viniferin-Induced Apoptosis through Downregulation of SIRT1 in Non-Small Cell Lung Cancer Cells.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Therapeutic Potential of Luteolin on Cancer.Vaccines · 2023Review
- Luteolin overcomes acquired resistance to osimertinib in non-small cell lung cancer cells by targeting the HGF-MET-Akt pathway.American journal of cancer research · 2023Article
- Formulation and Evaluation of Luteolin-Loaded Nanovesicles:ACS omega · 2022Article
- Targeting LIMK1 with luteolin inhibits the growth of lung cancer in vitro and in vivo.Journal of cellular and molecular medicine · 2021Article
- Luteolin alters MUC1 extracellular domain, sT antigen, ADAM-17, IL-8, IL-10 and NF-κB expression inBiomedical reports · 2021Article
- Review
- Luteolin attenuates migration and invasion of lung cancer cells via suppressing focal adhesion kinase and non-receptor tyrosine kinase signaling pathway.Nutrition research and practice · 2020Article
- Mapping Pharmacological Network of Multi-Targeting Litchi Ingredients in Cancer Therapeutics.Frontiers in pharmacology · 2020Article
- FlavoDb: a web-based chemical repository of flavonoid compounds.3 Biotech · 2019Article
- Progress in Research on the Role of Flavonoids in Lung Cancer.International journal of molecular sciences · 2019Review
- Delivery of natural phenolic compounds for the potential treatment of lung cancer.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2019Review
- Luteolin inhibits cell cycle progression and induces apoptosis of breast cancer cells through downregulation of human telomerase reverse transcriptase.Oncology letters · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Luteolin is a falconoid compound, which exhibits anticancer properties, however, its contribution to Sirt1-mediated apoptosis in human non-small cell lung cancer remains to be elucidated. The present study confirmed that the anticancer effect of luteolin on NCI‑H460 cells was through Sirt1‑mediated apoptosis. The NCI‑H460 cells were treated with different concentrations of luteolin, and a 3‑(4,5‑dimethyl‑2‑thiazolyl)‑2,5‑diphnyl‑2H‑tetrazolium bromide assay, cell cycle analysis and annexin‑V/fluorescein isothiocyanate and propidium double staining were performed to assess the apoptotic effect of luteolin. Wound healing and Transwell assays were performed to confirm the inhibition of NCI‑H460 cell migration. The protein levels of Sirt1 were knocked down in the NCI‑H460 cells using a lentivirus to further investigate the role of this protein, and the expression levels of the apoptotic associated proteins, Bad, Bcl‑2, Bax, caspase‑3 and Sirt1, were measured using western blotting. The results of the present study demonstrated that luteolin exerted an anticancer effect against NCI‑H460 cells through Sirt1‑mediated apoptosis and the inhibition of cell migration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.